Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals
- Category: DNA RNA and Cells
- Published on Tuesday, 08 May 2007 04:00
- Hits: 2179
WORCESTER, MA, USA | May 7, 2007 | Advanced Cell Technology, Inc. (OTCBB: ACTC) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors—known as hemangioblasts—from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.
“The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions,” said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. “Our results suggest the possibility of using nature’s early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack.”
“We have developed for the first time a simple and highly scalable source of human hemangioblasts,” stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper. “These proprietary cells represent a new and distinctly different population of cells that can be differentiated into vascular structures and multiple hematopoietic cell types. The elimination of serum and other animal components from the system, as well as the ability to generate an unlimited supply of these cells, will be important for future preclinical and human studies.”
When the cells were injected into animals that had damage to their retina due to diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24-48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
“These cells were able to generate functional blood vessels in the presence of severe tissue injury, as well as in chronic disease states,” says Maria Grant, M.D., Professor of Pharmacology at the University of Florida, and an author on the paper. “These cells have a robust vascular reparative ability under what is typically considered very adverse growth conditions making them potentially ideal for treatment of diabetic vascular complications where profound tissue compromise exists and healing is typically severely compromised.”
“While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit many Americans suffering from vascular disease,” stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. “ACT is committed to moving this technology from the laboratory into the clinic. We plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year.”
The researchers of the paper from Advanced Cell Technology collaborated with scientists from the University of Florida, Gainesville, Florida, and the Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York. The paper’s other authors are Qiang Feng of ACT, Sergio Caballero of the University of Florida, and Yu Chen and Malcolm A.S. Moore, DPhil, of MSKCC.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, please visit: www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.